Condition
Allergic Asthma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 109 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab BiosimilarNCT07425639 · 2025-10-02
RECRUITINGCreating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA StudyNCT07055542 · 2025-08-27
RECRUITINGSafety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without AsthmaNCT06960382 · 2025-08-20
RECRUITINGEfficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsNCT07342803 · 2025-01-25
RECRUITINGEvaluate the Efficacy and Safety of FB825 in Adult With Allergic AsthmaNCT05008965 · 2021-07-27
RECRUITINGModified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation SyndromeNCT07352488 · 2026-01-15
NOT_YET_RECRUITINGA Study on the Efficacy of Environmental Probiotics in Patients With Cat Hair AllergiesNCT07114133 · 2025-06-30
ENROLLING_BY_INVITATIONA Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic AsthmaNCT06592768 · 2024-11-26
TERMINATEDTrial of JYB1904 in Patients With Allergic AsthmaNCT06438757 · 2024-06-19
COMPLETEDA Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma PatientsNCT06486662 · 2024-06-14
COMPLETEDCombination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe AsthmaNCT06771934 · 2024-06-01
UNKNOWNEvaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic RhinitisNCT06151938 · 2023-11-21
UNKNOWNClinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractNCT05641272 · 2023-11-01
NOT_YET_RECRUITINGThe Impact of Breath Exercises by Telemedicine in Patients Aged 8-18 Years With a Diagnosis of AsthmaNCT05749237 · 2023-02-03
UNKNOWNA Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy VolunteersNCT06494345 · 2023-01-15
COMPLETEDChanges in Eosinophil Cationic Protein and Sputum Eosinophils Following Allergen ImmunotherapyNCT07694947 · 2023-01-01
COMPLETEDEfficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/RhinoconjunctivitisNCT05400811 · 2022-12-01
UNKNOWNIntralymphatic Immunotherapy With Polvac Grass & Rye Allergen ExtractNCT05297760 · 2022-02-10
COMPLETEDAirway Immune Response to Allergens (Use Lay Language Here)NCT04619017 · 2021-10-28
UNKNOWNAndosan in Allergic and Asthma PatientsNCT05192720 · 2021-08-31
COMPLETEDEfficacy of Face Mask in Reducing Respiratory Allergic Symptoms in Birch-allergic Subjects in ALYATEC Exposure ChamberNCT06267261 · 2021-06-07
COMPLETEDA Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)NCT04699604 · 2021-04-28
COMPLETEDKinetics of Nasal Cytokine Responses to Mechanical StimulationNCT04878237 · 2021-03-25
COMPLETEDEnvironmental Pollutants and Their Effects on Respiratory AllergyNCT04902989 · 2021-03-10
UNKNOWNEffectiveness and Safety of Omalizumab in Children With Allergic Asthma.NCT05424523 · 2021-02-25
COMPLETEDEfficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic AsthmaNCT05813470 · 2021-01-18
COMPLETEDEffects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic PatientsNCT04673591 · 2020-12-09
COMPLETEDabioSCOPE IgE Assay to Aid in the Diagnosis of AllergiesNCT04442932 · 2020-11-15
WITHDRAWNTiotropium Efficacy Against Allergen Induced Early Asthmatic ResponsesNCT04648813 · 2020-11-13
COMPLETEDTyrosine Allergoid Paediatric and Adult StudyNCT05186025 · 2020-11-06
ACTIVE_NOT_RECRUITINGAnalytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method CorrelationNCT04401631 · 2020-11-01
WITHDRAWNNon-coding RNAs Analysis of Eosinophil Subtypes in AsthmaNCT04542902 · 2020-10-01
UNKNOWNAnti-inflammatory Effects GlycopyrroniumNCT04259164 · 2020-09-10
COMPLETEDGender Differences and SNPs in Asthmatic PatientsNCT04567212 · 2020-08-01
UNKNOWNInfluence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) LevelsNCT04389034 · 2020-04-22
COMPLETEDTowards Targeting the ORigin of the Inflammatory Cascade in Allergic AsthmaNCT04264377 · 2020-02-07
UNKNOWNDocumentation of Efficacy of Intralymphatic Allergen ImmunotherapyNCT05191186 · 2020-02-01
COMPLETEDEffect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With AsthmaNCT04109534 · 2019-10-01
UNKNOWNImmune Response Features in Allergic Airway DiseasesNCT04352088 · 2019-05-01
UNKNOWNImpact of Pollution on Allergic Rhinitis and Sleep Quality: the POLLAR StudyNCT03776773 · 2019-04-08
COMPLETEDDiagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTestNCT03820154 · 2019-03-01
UNKNOWNIntervention in Chronic Pediatric Patients and Their Families.NCT04476433 · 2019-02-04
COMPLETEDValidation of Combined Symptom Medication Score (cSMS) in Allergic PatientsNCT03850626 · 2018-09-09
COMPLETEDNasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid TreatmentNCT03431961 · 2018-03-07
UNKNOWNChildren's Respiratory and Environmental WorkgroupNCT03213184 · 2017-12-26
COMPLETEDHouse Dust Mite Induced Inflammasome Activation on Corticosteroid ResistanceNCT03307278 · 2017-11-30
WITHDRAWNRole of Extracellular Matrix in the Development of Airway Remodeling in AsthmaNCT03388359 · 2017-06-01
UNKNOWNValidation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With AsthmaNCT04678063 · 2017-04-10
COMPLETEDPemirolast in Allergen Challenge (PEMAG)NCT03119714 · 2016-11-01
TERMINATEDEffect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 ExposureNCT02911688 · 2016-09-01
COMPLETEDValidation of Strasbourg Environmental Exposure Chamber ALYATEC in Mite Allergic Subjects With AsthmaNCT04663880 · 2016-08-30
COMPLETEDAsthMatic Inflammation and Neurocircuitry Activation (MINA)NCT02764437 · 2016-07-28
COMPLETEDTo Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This SusceptibilityNCT02767973 · 2016-06-09
SUSPENDEDStudy of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic RhinitisNCT02908360 · 2015-07-10
COMPLETEDBronchial Allergen Provocation Tests in Asthmatics in GuangzhouNCT02504528 · 2015-07-01
COMPLETEDSpecific Immunotherapy for Allergic ChildNCT02965612 · 2015-05-01
UNKNOWNDietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic ManifestationsNCT03861910 · 2014-12-01
COMPLETEDEfficacy Of Bacterial Lysate In Asthmatic ChildrenNCT02541331 · 2014-07-01
COMPLETEDEosinophil Induced Remodelling in AsthmaNCT02648074 · 2014-03-01
COMPLETEDAnalysis of Fel d 1-specific T Cells After Airway Allergen Challenge in AsthmaNCT01612715 · 2014-01-29
COMPLETEDCommon interventions
PlaceboDRUG19omalizumabDRUG13Bronchial challenge with allergenPROCEDURE3omalizumabBIOLOGICAL3PlaceboBIOLOGICAL3AER 001DRUG2Blood CollectionDEVICE2Co-culture formationOTHER2Dermatophagoides pteronyssinus allergenBIOLOGICAL2PlaceboOTHER23,000 MM09BIOLOGICAL19,000 MM09BIOLOGICAL1Airway smooth muscle cellsBIOLOGICAL1Albuterol sulfateDRUG1Allergen immunotherapyBIOLOGICAL1Allergen Immunotherapy ExtractDRUG1Allergen-specific immunotherapy(AIT)BIOLOGICAL1ALUTARD SQ® Felis domesticusDRUG1AndosanDIETARY_SUPPLEMENT1Asthma therapiesDRUG1AZD8848DRUG1Blood samplingPROCEDURE1BriquilimabDRUG1Bronchial allergen provocation (BAP)DIAGNOSTIC_TEST1BronchoscopyPROCEDURE1
Leading sponsors
Novartis Pharmaceuticals
6
Genentech, Inc.
5
Johann Wolfgang Goethe University Hospital
5
Lithuanian University of Health Sciences
5
Alyatec
3
University of Wisconsin, Madison
3
Abionic SA
2
Aerovance, Inc.
2
ALK-Abelló A/S
2
Allergy Therapeutics
2
AstraZeneca
2
Creighton University
2
Inmunotek S.L.
2
Laboratorios Leti, S.L.
2
University Medical Center Groningen
2
Trial status mix
COMPLETED71
UNKNOWN19
RECRUITING5
WITHDRAWN5
TERMINATED3
ENROLLING_BY_INVITATION2
NOT_YET_RECRUITING2
ACTIVE_NOT_RECRUITING1
SUSPENDED1
Phase mix
NA29
PHASE225
PHASE315
PHASE110
PHASE49
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.